Treatment with doses as low as 12.5 nM resulted in an efficient reduction of DNMT1 and DNMT3A protein levels after six days of treatment, which persisted throughout the duration of the experiment (i.e., 12 days) in all investigated MM cell lines (Supplementary Fig. 1a). The gene discussed is DNMT3A; the disease is Miyoshi myopathy.